340B Reform Remains Elusive Even As Spending Increases

Total purchases at 340B prices by 2021 are projected to exceed $23 bil – more than total Medicare Part B drug reimbursement in 2014.

RollOfDollarswithPills_1200x675

Industry, advocates and legislators are in agreement that there must be changes to the federal 340B Drug Discount Program to control its growth, but it remains unclear which direction Congress will go to solve the issue.

Ted Alexander, a senior legislative assistant for House Energy & Commerce Health Subcommittee member Rep. Chris Collins (R-N.Y.), acknowledged that...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet